News | November 10, 2025
Marksans Pharma's Goa unit clears FDA inspection
The said inspection concluded with Zero Form 483 observation
The said inspection concluded with Zero Form 483 observation
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The facility has been classified as Voluntary Action Indicated
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Subscribe To Our Newsletter & Stay Updated
